Doxazosin mesilate slow releasing preparation

A technology of doxazosin mesylate and sustained-release preparation, applied in the field of medicine, can solve the problems of patient health threat, inconvenience to patients and doctors, etc., and achieve the effects of reducing the number of doses, being convenient to carry, and reducing the incidence of side effects

Inactive Publication Date: 2008-06-04
BEIJING SHIQIAO BIOPHAM
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This way of taking multiple medications not only brings inconvenience to patients and doctors, but also threatens the health of patients if there is a mistake in the dosage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Doxazosin mesilate slow releasing preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The present embodiment 1 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:

[0019] Doxazosin Mesylate 2.7%

[0020] HPMCK4M (Methocel K15MCR) 45%

[0021] Lactose 51.6%

[0022] Magnesium Stearate 0.7%

[0023] HPMCK4M is a hydrophilic polymer, which is a skeleton material in this preparation, which swells with water or digestive juice to form a gel barrier to control the diffusion of doxazosin mesylate and achieve the purpose of sustained release.

[0024] Among them, HPMCK4M can be replaced by different dosages of HPMCK100LV, HPMCK15M or HPMCK100M, or used in combination to adjust the drug release curve.

Embodiment 2

[0026] The present embodiment 2 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:

[0027] Doxazosin Mesylate 3%

[0028] Carbopol 45%

[0029] Lactose 51%

[0030] Magnesium Stearate 1%

[0031] Hydrophilic polymer polycarboxyethylene (carbomer) is used as the skeleton material, which swells with water or digestive juice to form a gel barrier to control the diffusion of doxazosin mesylate and achieve the purpose of sustained release.

Embodiment 3

[0033] The present embodiment 3 tablet that adopts the known method of pharmaceutical industry to make contains following composition by weight percentage:

[0034] Doxazosin Mesylate 3%

[0035] Sodium Alginate 37%

[0036] Calcium Alginate 3%

[0037] Lactose 56%

[0038] Magnesium Stearate 1%

[0039] The insoluble salt and soluble salt of the hydrophilic polymer alginic acid are used as the skeleton material, which swells with water or digestive juice to form a cross-linked gel barrier to control the diffusion of doxazosin mesylate and achieve the purpose of sustained release.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides orally taken slow releasing Doxazosin mesilate preparation. The medicine preparation contains Doxazosin mesilate in 1-10 wt%, supplementary material for slow releasing 10-70 wt% and other supplementary material. The supplementary material for slow releasing is hydroxypropyl methyl cellulose, ethyl cellulose, polyacrylate resin, polyhydroxy ethylene and / or water soluble / insoluble alginate. Compared with fast released preparation, the slow releasing Doxazosin mesilate preparation of the present invention can maintain the effective period of 24 hr, stable blood medicine concentration, high curative effect, improved taste, less medicine taking times and less side effect. The present invention is used widely in the treatment of benign prostate hyperplasia, hypertension and other diseases.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, specifically, it is a sustained-release preparation of doxazosin mesylate for treating diseases such as benign prostatic hyperplasia and hypertension, which is administered once a day. Background technique: [0002] Doxazosin mesylate is a selective alpha 1 Adrenergic blockers. By blocking α receptors, it can expand blood vessels, reduce vascular resistance, and lower blood pressure; by selectively blocking α-adrenergic receptors in the smooth muscle matrix, capsule and bladder neck of the prostate, it can improve the symptoms of benign prostatic hyperplasia patients. been widely applied. Doxazosin mesilate is easily soluble in dimethylsulfoxide; soluble in dimethylamide; slightly soluble in methanol, ethanol and water (0.8%, 25°C); insoluble in acetone and dichloromethane; extremely insoluble in chloroform. [0003] This product is mainly absorbed in the gastrointestinal tract, and the abs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/502A61K9/22A61K9/28A61K9/52A61K47/38A61K47/30A61P13/08A61P9/12
Inventor 潘卫三赵颖
Owner BEIJING SHIQIAO BIOPHAM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap